The biotech’s licensing pact with Pfizer, revealed last week, will leverage its adjuvant vaccine platform in the development ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

The business may not be as strong as its performance this year suggests.

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to two infectious disease vaccines. The deal grants Pfizer non-exclusive ...

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

Gaithersburg-based Novavax said Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, and ...